Cantargia presents new preclinical data on antibody CAN10 at IMMMUNOLOGY2021
Cantargia AB today announced that new data on the antibody CAN10 will be presented at the annual meeting of the American Association of Immunologists (AAI), Virtual IMMUNOLOGY2021. The abstract has now been published and discloses that the interleukin-1 receptor accessory binding protein (IL1RAP) reactive antibody CAN10 counteract inflammation and disease development in models of peritonitis, psoriasis and myocarditis.Cantargia develops antibody-based pharmaceuticals against IL1RAP. The lead project CAN04 is in phase IIa clinical development for treatment of cancer while the second project